公开(公告)号：US20240189354A1

公开(公告)日：2024-06-13

申请号：US18393322

申请日：2023-12-21

Applicant: CELLECTIS SA

Inventor： Julianne SMITH ,  Phillippe DUCHATEAU ,  Murielle DERRIEN

IPC: A61K35/17 ,  A61K31/365 ,  A61K39/395 ,  A61P35/02 ,  C07K14/705 ,  C07K14/725 ,  C07K16/28

CPC classification number: A61K35/17 ,  A61K31/365 ,  A61K39/39558 ,  A61P35/02 ,  C07K14/7051 ,  C07K14/70517 ,  C07K14/70578 ,  C07K16/2803 ,  C07K2317/34 ,  C07K2317/53 ,  C07K2317/622

Abstract: The present invention relates to an engineered immune cell endowed with CD22 Chimeric Antigen Receptors (CD22 CAR) with a deletion in the TRAC gene that is able to redirect immune cell specificity and reactivity toward selected tumor cells. The engineered immune cells endowed with such CARs are particularly suited for treating relapsed refractory CD22 expressing cancers.

公开(公告)号：US20230201260A1

公开(公告)日：2023-06-29

申请号：US18056544

申请日：2022-11-17

Applicant: CELLECTIS

Inventor： Roman GALETTO ,  Agnes GOUBLE ,  Stephanie GROSSE ,  Cécile SCHIFFER-MANNIOUI ,  Laurent POIROT ,  Andrew SCHARENBERG ,  Julianne SMITH

IPC: A61K35/17 ,  C12N5/0783 ,  C07K16/28 ,  C07K14/725 ,  C07K14/705 ,  C12N15/85

CPC classification number: A61K35/17 ,  C12N5/0636 ,  C07K16/2803 ,  C07K14/7051 ,  C07K14/70517 ,  C07K14/70521 ,  C07K14/70578 ,  C07K16/28 ,  C12N15/85 ,  C07K2317/622 ,  C12N2501/51 ,  C12N2501/515 ,  C12N2502/99 ,  C07K2319/00 ,  C12N2501/39 ,  C12N2501/599 ,  A61K38/00

Abstract: The present invention relates to methods for developing engineered T-cells for immunotherapy that are non-alloreactive. The present invention relates to methods for modifying T-cells by inactivating both genes encoding T-cell receptor and an immune checkpoint gene to unleash the potential of the immune response. This method involves the use of specific rare cutting endonucleases, in particular TALE-nucleases (TAL effector endonuclease) and polynucleotides encoding such polypeptides, to precisely target a selection of key genes in T-cells, which are available from donors or from culture of primary cells. The invention opens the way to standard and affordable adoptive immunotherapy strategies for treating cancer and viral infections.

公开(公告)号：US20180291079A1

公开(公告)日：2018-10-11

申请号：US15575707

申请日：2016-05-20

Applicant: Cellectis

Inventor： Julianne SMITH ,  Cècile SCHIFFER-MANNIOUI

IPC: C07K14/725 ,  C07K14/705 ,  C07K14/735 ,  C07K16/30 ,  C12N5/0783

Abstract: The present invention relates to Chimeric Antigen Receptors (CAR) that are recombinant chimeric proteins able to redirect immune cell specificity and reactivity toward selected membrane antigens, and more particularly in which extracellular ligand binding is a scFV derived from a GD3 monoclonal antibody, conferring specific immunity against GD3 positive cells. The engineered immune cells endowed with such CARs are particularly suited for treating solid tumors such as melanomas, carcinomas or liquid tumor such as T-cell lymphoblastic leukemia.

公开(公告)号：US20180002427A1

公开(公告)日：2018-01-04

申请号：US15546619

申请日：2016-01-25

Applicant: CELLECTIS

Inventor： Julianne SMITH ,  Julien VALTON ,  Philippe DUCHATEAU ,  Alexandre JUILLERAT ,  Arvind RAJPAL ,  Barbra Johnson SASU

IPC: C07K16/28 ,  C12N5/00 ,  C07K16/30 ,  A61K39/00 ,  A61K35/17 ,  C12N5/0783 ,  C07K14/725

CPC classification number: C07K16/2866 ,  A61K35/17 ,  A61K39/0011 ,  A61K39/39558 ,  A61K2039/505 ,  A61K2039/5156 ,  A61K2039/5158 ,  A61K2039/6056 ,  A61K2039/64 ,  C07K14/7051 ,  C07K14/70517 ,  C07K14/70535 ,  C07K14/70578 ,  C07K16/2803 ,  C07K16/2887 ,  C07K16/3061 ,  C07K2317/24 ,  C07K2317/53 ,  C07K2317/56 ,  C07K2317/622 ,  C07K2319/00 ,  C07K2319/02 ,  C07K2319/03 ,  C12N5/0093 ,  C12N5/0636 ,  C12N5/0638 ,  C12N2510/00 ,  G01N15/1031 ,  G01N15/14 ,  G01N2015/008 ,  G01N2015/1006 ,  G01N2015/1081 ,  G01N2015/149

Abstract: The present invention relates to a new generation of chimeric antigen receptors (CAR) referred to as multi-chain CARs, which are made specific to the antigen CLL1. Such CARs aim to redirect immune cell specificity and reactivity toward malignant cells expressing the tumor antigen CLL1. The alpha, beta and gamma polypeptides composing these CARs are designed to assemble in juxtamembrane position, which forms flexible architecture closer to natural receptors, that confers optimal signal transduction. The invention encompasses the polynucleotides, vectors encoding said multi-chain CAR and the isolated cells expressing them at their surface, in particularly for their use in immunotherapy. The invention opens the way to efficient adoptive immunotherapy strategies for treating cancer, especially leukemia.

公开(公告)号：US20230056268A1

公开(公告)日：2023-02-23

申请号：US17716102

申请日：2022-04-08

Applicant: CELLECTIS

Inventor： Roman GALETTO ,  Agnes GOUBLE ,  Stephanie GROSSE ,  Cécile SCHIFFER-MANNIOUI ,  Laurent POIROT ,  Andrew SCHARENBERG ,  Julianne SMITH

IPC: A61K35/17 ,  C12N9/22 ,  C12N5/0783

Abstract: The present invention relates to methods for developing engineered T-cells for immunotherapy and more specifically to methods for modifying T-cells by inactivating at immune checkpoint genes, preferably at least two selected from different pathways, to increase T-cell immune activity This method involves the use of specific rare cutting endonucleases, in particular TALE-nucleases (TAL effector endonuclease) and polynucleotides encoding such polypeptides, to precisely target a selection of key genes in T-cells, which are available from donors or from culture of primary cells. The invention opens the way to highly efficient adoptive immunotherapy strategies for treating cancer and viral infections.

公开(公告)号：US20210220405A1

公开(公告)日：2021-07-22

申请号：US17198505

申请日：2021-03-11

Applicant: Cellectis

Inventor： Roman GALETTO ,  Agnes GOUBLE ,  Stephanie GROSSE ,  Cecile MANNIOUI ,  Laurent POIROT ,  Andrew SCHARENBERG ,  Julianne SMITH

IPC: A61K35/17 ,  C07K14/705 ,  C12N5/0783 ,  C07K14/725 ,  C07K16/28

Abstract: A method of expanding TCRalpha deficient T-cells by expressing pTalpha or functional variants thereof into said cells, thereby restoring a functional CD3 complex. This method is particularly useful to enhance the efficiency of immunotherapy using primary T-cells from donors. This method involves the use of pTalpha or functional variants thereof and polynucleotides encoding such polypeptides to expand TCRalpha deficient T-cells. Such engineered cells can be obtained by using specific rare-cutting endonuclease, preferably TALE-nucleases. The use of Chimeric Antigen Receptor (CAR), especially multi-chain CAR, in such engineered cells to target malignant or infected cells. The invention opens the way to standard and affordable adoptive immunotherapy strategies for treating cancer and viral infections.

公开(公告)号：US20210060080A1

公开(公告)日：2021-03-04

申请号：US17099614

申请日：2020-11-16

Applicant: Cellectis

Inventor： Roman GALETTO ,  Julianne SMITH ,  Andrew SCHARENBERG ,  Cécile SCHIFFER-MANNIOUI

IPC: A61K35/17 ,  C07K14/705 ,  C12N5/0783 ,  C07K14/725 ,  C07K16/28

Abstract: The present invention relates to chimeric antigen receptors (CAR). CARs are able to redirect immune cell specificity and reactivity toward a selected target exploiting the ligand-binding domain properties. In particular, the present invention relates to a Chimeric Antigen Receptor in which extracellular ligand binding is a scFV derived from a CD19 monoclonal antibody, preferably 4G7. The present invention also relates to polynucleotides, vectors encoding said CAR and isolated cells expressing said CAR at their surface. The present invention also relates to methods for engineering immune cells expressing 4G7-CAR at their surface which confers a prolonged “activated” state on the transduced cell. The present invention is particularly useful for the treatment of B-cells lymphomas and leukemia.

公开(公告)号：US20180000914A1

公开(公告)日：2018-01-04

申请号：US15546604

申请日：2016-01-25

Applicant: Cellectis

Inventor： Julien VALTON ,  Philippe DUCHATEAU ,  Alexandre JUILLERAT ,  Arvind RAJPAL ,  Barbra Johnson SASU ,  Julianne SMITH

IPC: A61K39/00 ,  C07K14/725 ,  C12N5/0783 ,  C07K14/735 ,  A61K39/395 ,  C07K16/28 ,  C07K14/705

CPC classification number: C07K16/2866 ,  A61K35/17 ,  A61K39/0011 ,  A61K39/39558 ,  A61K2039/505 ,  A61K2039/5156 ,  A61K2039/5158 ,  A61K2039/6056 ,  A61K2039/64 ,  C07K14/7051 ,  C07K14/70517 ,  C07K14/70535 ,  C07K14/70578 ,  C07K16/2803 ,  C07K16/2887 ,  C07K16/3061 ,  C07K2317/24 ,  C07K2317/53 ,  C07K2317/56 ,  C07K2317/622 ,  C07K2319/00 ,  C07K2319/02 ,  C07K2319/03 ,  C12N5/0093 ,  C12N5/0636 ,  C12N5/0638 ,  C12N2510/00 ,  G01N15/1031 ,  G01N15/14 ,  G01N2015/008 ,  G01N2015/1006 ,  G01N2015/1081 ,  G01N2015/149

Abstract: The present invention relates to Chimeric Antigen Receptors (CAR) that are recombinant chimeric proteins able to redirect immune cell specificity and reactivity toward selected membrane antigens, and more particularly in which extracellular ligand binding is a scFV derived from an anti-HSP70 monoclonal antibody, conferring specific immunity against HSP70 positive cells. The engineered immune cells endowed with such CARs are particularly suited for treating in particular leukemia.

公开(公告)号：US20160273003A1

公开(公告)日：2016-09-22

申请号：US15080232

申请日：2016-03-24

Applicant: Cellectis S.A.

Inventor： Philippe DUCHATEAU ,  Christophe PEREZ ,  Sylvia BRUNEAU ,  Jean-Pierre CABANIOLS ,  Julianne SMITH ,  Agnes GOUBLE

IPC: C12N15/90 ,  C07K14/435 ,  C12N15/86 ,  C12N9/22 ,  A61K38/46 ,  C12N7/00

CPC classification number: C12N15/907 ,  A01K67/0275 ,  A01K67/0278 ,  A01K2207/15 ,  A01K2217/00 ,  A01K2217/05 ,  A01K2227/105 ,  A01K2267/03 ,  A01K2267/0337 ,  A61K38/00 ,  A61K38/1709 ,  A61K38/465 ,  A61K48/00 ,  A61K48/0058 ,  C07K14/435 ,  C07K2319/81 ,  C12N7/00 ,  C12N9/22 ,  C12N15/1058 ,  C12N15/8509 ,  C12N15/86 ,  C12N15/90 ,  C12N2730/10143 ,  C12N2799/022 ,  C12N2800/80 ,  C12N2830/002 ,  C12N2830/55 ,  C12N2840/20 ,  C12N2840/44 ,  C12Y301/00 ,  C12Y301/21004

Abstract: A single chain homing endonuclease, comprising a first variant of I-CreI having the amino acid sequence of accession number pdb 1g9y and a second variant of I-CreI variant having the amino acid sequence of accession number pdb 1g9y in a single polypeptide.

Abstract translation: 单链归巢内切核酸酶，其包含具有登录号pdb 1g9y的氨基酸序列的I-CreI的第一变体和在单个多肽中具有登录号pdb 1g9y的氨基酸序列的I-CreI变体的第二变体。

公开(公告)号：US20160120905A1

公开(公告)日：2016-05-05

申请号：US14889686

申请日：2014-05-13

Applicant: CELLECTIS

Inventor： Roman GALETTO ,  Agnes GOUBLE ,  Stephanie GROSSE ,  Cécile SCHIFFER-MANNIOUI ,  Laurent POIROT ,  Andrew SCHARENBERG ,  Julianne SMITH

IPC: A61K35/17 ,  C12N5/0783

CPC classification number: A61K35/17 ,  A61K38/00 ,  C07K14/7051 ,  C07K14/70517 ,  C07K14/70521 ,  C07K14/70578 ,  C07K16/28 ,  C07K16/2803 ,  C07K2317/14 ,  C07K2317/24 ,  C07K2317/569 ,  C07K2317/622 ,  C07K2319/00 ,  C07K2319/03 ,  C07K2319/74 ,  C12N5/0636 ,  C12N2501/39 ,  C12N2501/51 ,  C12N2501/515 ,  C12N2501/599 ,  C12N2502/99 ,  C12N2510/00

Abstract: The present invention relates to methods for developing engineered T-cells for immunotherapy that are non-alloreactive. The present invention relates to methods for modifying T-cells by inactivating both genes encoding T-cell receptor and an immune checkpoint gene to unleash the potential of the immune response. This method involves the use of specific rare cutting endonucleases, in particular TALE-nucleases (TAL effector endonuclease) and polynucleotides encoding such polypeptides, to precisely target a selection of key genes in T-cells, which are available from donors or from culture of primary cells. The invention opens the way to standard and affordable adoptive immunotherapy strategies for treating cancer and viral infections.

Abstract translation: 本发明涉及用于开发非同种异体反应的用于免疫治疗的工程化T细胞的方法。 本发明涉及通过使编码T细胞受体的两个基因和免疫检查点基因失活来释放免疫应答的潜力来修饰T细胞的方法。 该方法包括使用特定的稀有切割内切核酸酶，特别是TALE-核酸酶（TAL效应子内切核酸酶）和编码这种多肽的多核苷酸，以精确地靶向T细胞中的关键基因的选择，其可从供体或从原代培养获得 细胞。 本发明开启了治疗癌症和病毒感染的标准和负担得起的过继免疫治疗策略的方法。